Gene Editing Market Research Report 2025-2029 - Biotech Leaders Drive Innovation as Gene Editing Becomes Key to Sustainable Solutions
Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Gene Editing Markets 2025-2029 by Application, Technology, Place, Industry and Product with Executive & Consultant Guides" report has been added to ResearchAndMarkets.com's offering.
This comprehensive view of the gene editing landscape highlights the technology's potential to drive transformative change. As breakthroughs become more frequent, businesses need to stay informed about the latest trends and projections. Those equipped with thorough market insights are poised to leverage these technologies effectively, ensuring competitive advantages in their respective fields.
Gene Editing is moving from strength to strength. CRISPR and similar tools are finding new uses in every area of biotechnology. It started with Medical applications by changing genes in living human cells. Uncurable diseases have already being cured. More are on the way.
The market for gene editing tools is witnessing a surge, with rapid growth driven by technological advances. These tools are broadening their reach beyond healthcare, offering groundbreaking possibilities in agriculture, biofuel production, and more. Major players in the biotechnology industry are spearheading research to develop innovative applications, ensuring continual market evolution.
Industry experts indicate that the gene editing industry is set to continue its rapid expansion. Companies and researchers are actively investigating diverse opportunities in areas such as crop improvement, pest control, and sustainable resource management. These developments position gene editing as a cornerstone technology, promising significant impacts on global food security and sustainable practices.
The gene editing market is becoming increasingly sophisticated, with new applications and technologies emerging regularly. As demand for more precise and efficient biotechnological solutions grows, the sector continues to attract substantial investment. Key players are focusing on research and development, strengthening their market positions, and pushing forward innovations to meet both current needs and future challenges.
Key Topics Covered:
1 Market Guides1.1 Strategic Situation Analysis1.2 Guide for Executives, Marketing, Sales and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors2 Introduction and Market Definition2.1 Methodology2.1.1 Methodology2.1.2 Sources2.1.3 Authors2.2 What is Gene Editing?2.3 The CRISPR Example2.3.1 What is CRISPR?2.3.2 The CRISPR Family2.4 Chromosomes, Genes and Epigenetics2.4.1 Chromosomes2.4.2 Genes2.4.3 Epigenetics2.5 Market Definition2.5.1 Revenue Market Size2.6 Perspective: Healthcare Spending2.6.1 Global Healthcare Spending2.6.2 Spending on Healthcare and Pharmaceuticals2.6.3 Spending on Diagnostics2.6.4 Important Role of Insurance for Medical Services3 Market Structure3.1 Market Structure Therapeutics3.1.1 Research and Development (R&D) Companies3.1.2 Biotechnology Companies3.1.3 Generic Drug Manufacturers3.1.4 Big Pharmaceuticals3.1.5 Contract Research Organizations (CROs)3.1.6 Contract Manufacturing Organizations (CMOs)3.1.7 Specialty Pharmaceutical Companies3.1.8 Pharmaceutical Distributors3.1.9 Retail Pharmacies3.1.10 Wholesalers3.1.11 Online Pharmacies3.1.12 Health Technology Companies3.1.13 Pharmacy Benefit Managers (PBMs)3.1.14 Clinical Laboratories3.1.15 Medical Device Companies3.1.16 Regulatory Bodies3.2 Market Structure Diagnostics3.2.1 Academic Research Lab3.2.2 Diagnostic Test Developer3.2.3 Instrumentation Supplier3.2.4 Chemical/Reagent Supplier3.2.5 Pathology Supplier3.2.6 Independent Clinical Laboratory3.2.7 Public National/regional Laboratory3.2.8 Hospital Laboratory3.2.9 Physicians Office Lab (POLS)3.2.10 Audit Body3.2.11 Certification Body4 Market Trends4.1 Factors Driving Growth4.1.1 Cell Therapy4.1.2 Gene Therapy4.1.3 The New Agriculture4.1.4 Genetics and Cell Metabolism4.2 Factors Limiting Growth4.2.1 The Cost Curve4.2.2 Time and Trials4.2.3 The Price Barrier5 Recent Developments in Gene Editing5.1 Recent Developments - Importance and How to Use This Section5.1.1 Importance of These Developments5.1.2 How to Use This Section5.2 CRISPR tool allows for remote-controlled gene-editing5.3 CRISPR Making Sweeter Tomatoes5.4 Researchers Create gene-edited prawns5.5 Gene Editing Corrects Cystic Fibrosis5.6 CRISPR gene editing to change healthcare?5.7 CrisprBits Collaborates With MolBio Diagnostics5.8 Sherlock Bioscience to Launch Free AI-Based Operating System5.9 Sherlock Biosciences to Acquire Sense Biodetection5.10 CRISPR Enzyme Discovery Opens New Applications5.11 Sherlock Biosciences Adds Ambient Amplification to Toolkit5.12 Rice University Adapts CRISPR Enzyme5.13 Princeton Group Develops Cas13 Assay for Point-of-Care Use5.14 Proof Dx Plans Infectious Disease, Oncology Tests for CRISPR-Based POC System5.15 Sherlock Biosciences Raises $80M5.16 Broad Institute Considers CRISPR Respiratory Panels to Replace PCR5.17 Medix Biochemica Acquires MyPols Biotec5.18 Mammoth Biosciences High-Throughput CRISPR-Based COVID Test Gets EUA5.19 Genome Diagnostics Makes €1M Investment in Scope Biosciences5.20 CRISPR Test Could be used for Asymptomatic Screening5.21 Mammoth Biosciences, Agilent to Comarket CRISPR-Based SARS-CoV-2 Test5.22 Pandemic Accelerates Development of CRISPR Diagnostics5.23 ERS Genomics Licenses CRISPR Patents to Vivlion5.24 Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test5.25 ERS Genomics, FASMAC to Commercialize CRISPR-Cas95.26 The Nobel Prize in Chemistry 2020 - CRISPR Wins6 Key Companies6.1 10x Genomics, Inc.6.2 4D Molecular Therapeutics6.3 Abeona Therapeutics6.4 Acrigen Biosciences6.5 Adarx Pharmaceuticals6.6 Adverum Biotechnologies6.7 Affini-T Therapeutics6.8 Agilent6.9 Arbor Biotechnologies6.10 Arcturus Therapeutics6.11 Axxam6.12 Beam Therapeutics6.13 Beckman Coulter Diagnostics (Danaher)6.14 Becton, Dickinson and Company6.15 Binx Health6.16 bioMerieux Diagnostics6.17 Bio-Rad Laboratories, Inc.6.18 Bluebird Bio6.19 Caribou Biosciences6.20 Cell Microsystems6.21 Cellenion (BICO)6.22 Century Therapeutics6.23 Chroma Medicine6.24 Creative Biogene6.25 Crispr Therapeutics6.26 Editas Medicine6.27 ERS Genomics6.28 FASMAC6.29 Genscript Biotech6.30 Illumina6.31 Inscripta6.32 Intellia Therapeutics6.33 J&J Innovative Medicine6.34 Locus Biosciences6.35 Mammoth Biosciences6.36 Metagenomi6.37 Myllia Biotechnology6.38 Namocell6.39 NRGene6.40 Poseida Therapeutics6.41 Precision Biosciences6.42 Prime Medicine6.43 Proof Diagnostics6.44 Regeneron Pharmaceuticals6.45 Revvity6.46 Roche Diagnostics6.47 Sherlock Biosciences6.48 Thermo Fisher Scientific6.49 Twist Bioscience6.50 Verve Therapeutics6.51 Vivlion6.52 Wave Life Science7 The Global Market for Gene Editing7.1 Global Market Overview by Country7.2 Global Market by Application - Overview7.3 Global Market Technology - Overview7.4 Global Market Type - Overview7.5 Global Market Industry - Overview7.6 Global Market Product - Overview8 Gene Editing Markets - By Application8.1 Cell Line8.2 Plant8.3 Animal8.4 Cell Therapy8.5 Gene Therapy8.6 Diagnostics8.7 Research9 Global Gene Editing Markets - by Technology9.1 Crispr9.2 Talens9.3 ZFN9.4 Meganuclease10 Gene Editing Markets - by Place10.1 In Vivo10.2 Ex Vivo10.3 In Vitro11 Gene Editing Markets - by Industry11.1 Pharma11.2 Clinical11.3 Academic11.4 Contract12 Global Gene Editing Markets - by Product12.1 Instruments12.2 Cells12.3 Reagents13 Appendices13.1 United States Medicare System: laboratory Fees Schedule13.2 The Most Used IVD Assays13.3 The Highest Grossing Assays13.4 The Whole Genome Sequence of SARS-CoV-213.5 Global Listing of Sequencing Establishments - Location & Contacts
For more information about this report visit https://www.researchandmarkets.com/r/ktk8g
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 hours ago
- Business Upturn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of GSK plc ('GSK' or the 'Company') (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether GSK and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On July 17, 2025, GSK issued a press release announcing 'that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.' On this news, GSK's American Depositary Receipt ('ADR') price fell $1.81 per share, or 4.73%, to close at $36.47 per share on July 17, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See . Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle PeytonPomerantz LLP [email protected] 646-581-9980 ext. 7980
Business Upturn
5 hours ago
- Business Upturn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ('Ultragenyx' or the 'Company') (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On July 9, 2025, Ultragenyx and its development partner Mereo BioPharma Group plc issued a press release 'announc[ing] that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]' Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur 'around the end of the year.' On this news, Ultragenyx's stock price fell $10.41 per share, or 25.11%, to close at $31.04 per share on July 10, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See . Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle PeytonPomerantz LLP [email protected] 646-581-9980 ext. 7980
Business Upturn
5 hours ago
- Business Upturn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KBR, Inc.
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of KBR, Inc. ('KBR' or the 'Company') (NYSE: KBR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether KBR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On June 20, 2025, KBR issued a press release announcing that 'HomeSafe Alliance, a KBR . . . Joint Venture, informed us on June 18, 2025, that U.S. Transportation Command (TRANSCOM) has terminated HomeSafe's role in the Global Household Goods Contract, a contract designed to improve the moving system for military service members and their families.' On this news, KBR's stock price fell $3.85 per share, or 7.29%, to close at $48.93 per share on June 20, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLP [email protected] 646-581-9980 ext. 7980
